Cross-Immunity in Chickens Using Seven Isolates of Avian Infectious Bronchitis Virus

Ms, Hofstad

doi:10.2307/1589995

Cited by 60 publications

(42 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The phenomenon of IBV cross-protection has been recognized for many years (Hofstad, 1981;Cook et al ., 1999) and has been attributed to the immune response to shared S1 as well as other IBV gene epitopes (Cavanagh et al ., 1997). Immunization with a bivalent vaccine containing the Mass and Ark strains provided cross-protection against challenge with IBV field strains (Gelb et al ., 1991).…”

Section: Resultsmentioning

confidence: 99%

S1 gene characteristics and efficacy of vaccination against infectious bronchitis virus field isolates from the United States and Israel (1996 to 2000)

Weisman²,

et al. 2005

View full text Add to dashboard Cite

The S1 genes of isolates of avian coronavirus infectious bronchitis virus (IBV) from commercial chickens in the US and Israel (20 isolates from each country) were studied using reverse transcription-polymerase chain reaction restriction fragment length polymorphism and sequencing. Partial sequences spanning the amino terminus region of S1 from amino acid residues 48 to 219, based on the Beaudette strain, were used for analysis. Phylogenetic clustering and high-sequence identity values were used to identify isolates that appeared to be derived from live IBV vaccines used in the two countries. Novel variant strains, unrelated by S1 sequencing and restriction fragment length polymorphism analyses to reference and vaccine strains, were also identified. Based on S1 sequence identity to available vaccines, the potential to use vaccination to control IBV infections was evaluated. Vaccination with commercial live strains Massachusetts (Mass), Arkansas (Ark) or DE/072/92, generally produced immunity against vaccine-related field isolates displaying high S1 sequence similarities (]/90%) to the respective vaccine strains. Immunization with a bivalent vaccine containing the Mass and Ark strains provided good cross-protection, averaging 81% against challenge with five variant isolates from the US having amino acid identity values ranging from 62 to 69% to Mass and from 68 to 83% to Ark, respectively. In contrast, the H120 vaccine strain induced low levels of protection, ranging from 25 to 58% against variant field isolates from Israel with amino acid identity values from 65 to 67%.

show abstract

Section: Resultsmentioning

confidence: 99%

S1 gene characteristics and efficacy of vaccination against infectious bronchitis virus field isolates from the United States and Israel (1996 to 2000)

Weisman²,

et al. 2005

View full text Add to dashboard Cite

show abstract

“…However, somewhat higher PRV of 60 and 71% were observed, based primarily on one-way cross-challenge results for PA/5083/99 and PA/5344/98, as well as PA/171/99 and PA/1220/98. One-way crosschallenge protection has been reported previously (Hitchner et al ., 1964;Hofstad, 1981).…”

Section: Discussionmentioning

confidence: 99%

Infectious bronchitis virus S1 gene sequence comparison is a better predictor of challenge of immunity in chickens than serotyping by virus neutralization

2006

View full text Add to dashboard Cite

Five strains of infectious bronchitis virus isolated from commercial chickens from the state of Pennsylvania, USA during the years 1998 and 1999 were studied. The strains were selected for cross-challenge in specific pathogen free chickens and virus neutralization in chick embryos on the basis of partial S1 sequence amino acid identity values. The partial sequences analysed spanned the hypervariable amino terminus region of S1 from amino acid residues 48 to 219, based on the Beaudette strain. Using their S1 identity values, the strains represented a continuum of genetic, and thus antigenic, relationships. When compared with strain PA/5083/ 99, strain PA/Wolgemuth/98 had high sequence identity (96%) followed by PA/171/99 (85%), PA/5344/98 (70%) and PA/1220/98 (34%). The method of Archetti and Horsfall was used for calculating antigenic relatedness values of virus neutralization tests. The same formula was also applied to the percentage protection values of cross-challenge tests to derive protective relatedness values among the strains. The antigenic relatedness values, protective relatedness values, and the partial S1 sequence identity values were then analysed. The findings indicated partial S1 sequence identity values were more strongly correlated with protective relatedness values and than antigenic relatedness values.

show abstract

“…In experimental situations this can result in sterile immunity when challenged by virulent homologous virus within three weeks of vaccination. Sometimes, even in closely controlled experimental situations, 10% of vaccinated chicks do not respond with a protective immune response against challenge with the homologous strain [17,29,49,77,82,103]. These results show that chickens (out-bred, though with restricted sets of parental breeding stocks) are not uniform in their response to IBV vaccination.…”

Section: Live Vaccinesmentioning

confidence: 94%

“…First described in the 1930s in the USA, IB research has been dominated by the extensive genetic variation exhibited by the surface spike (S) protein gene, recognised half a century ago as antigenic variation. Specifically, virus neutralisation tests revealed the existence of serotypes (currently numbering dozens), which are poorly cross-protective [9,17,21,29,31,34,36,37,40,49,61,63,82].…”

Section: Introductionmentioning

confidence: 99%

Coronavirus avian infectious bronchitis virus

2007

View full text Add to dashboard Cite

-Infectious bronchitis virus (IBV), the coronavirus of the chicken (Gallus gallus), is one of the foremost causes of economic loss within the poultry industry, affecting the performance of both meat-type and egg-laying birds. The virus replicates not only in the epithelium of upper and lower respiratory tract tissues, but also in many tissues along the alimentary tract and elsewhere e.g. kidney, oviduct and testes. It can be detected in both respiratory and faecal material. There is increasing evidence that IBV can infect species of bird other than the chicken. Interestingly breeds of chicken vary with respect to the severity of infection with IBV, which may be related to the immune response. Probably the major reason for the high profile of IBV is the existence of a very large number of serotypes. Both live and inactivated IB vaccines are used extensively, the latter requiring priming by the former. Their effectiveness is diminished by poor cross-protection. The nature of the protective immune response to IBV is poorly understood. What is known is that the surface spike protein, indeed the amino-terminal S1 half, is sufficient to induce good protective immunity. There is increasing evidence that only a few amino acid differences amongst S proteins are sufficient to have a detrimental impact on cross-protection. Experimental vector IB vaccines and genetically manipulated IBVs -with heterologous spike protein genes -have produced promising results, including in the context of in ovo vaccination.

show abstract

Cross-Immunity in Chickens Using Seven Isolates of Avian Infectious Bronchitis Virus

Cited by 60 publications

References 5 publications

S1 gene characteristics and efficacy of vaccination against infectious bronchitis virus field isolates from the United States and Israel (1996 to 2000)

S1 gene characteristics and efficacy of vaccination against infectious bronchitis virus field isolates from the United States and Israel (1996 to 2000)

Infectious bronchitis virus S1 gene sequence comparison is a better predictor of challenge of immunity in chickens than serotyping by virus neutralization

Coronavirus avian infectious bronchitis virus

Contact Info

Product

Resources

About